Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model

Ocular Immunology and Inflammation

Volumn 17, Issue 3, 2009, Pages 195-200

  Olson, Jeffrey L ^a,b   Courtney, Robert J ^a   Rouhani, Behnaz ^a   Mandava, Naresh ^a   Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE   (United States)

Author keywords

Anakinra; Angiogenesis; Choroidal neovascularization; Interleukin 1; Macular degeneration

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRUCH MEMBRANE; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GROWTH INHIBITION; LASER COAGULATION; MALE; NONHUMAN; RAT; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DEXTRANS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCEIN ANGIOGRAPHY; FLUORESCEIN-5-ISOTHIOCYANATE; INJECTIONS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RATS; RATS, INBRED BN; VITREOUS BODY;

EID: 68849093907     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940802710705     Document Type: Article

References (38)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122: 564-572.
2. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891-1898.
3. Crum R, Szabo S, Folkman J, A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985;230:1375-1378.
4. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
5. Kvanta A, Algvere PV, Berglin L, Seregard S, Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
8. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
9. Vinores SA, XiaoWH, ZimmermanR,Whitcup SM,Wawrousek EF, Upregulation of vascular endothelial growth factor (VEGF) in the retinas of transgenic mice overexpressing interleukin-1beta (IL-1beta) in the lens and mice undergoing retinal degeneration. Histol Histopathol. 2003;18:797-810.
10. Asano-Kato N, Fukagawa K, Okada N, et al. TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts. Exp Eye Res. 2005;80:555-560.
11. Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD, Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol. 1997;24:1253-1259.
12. Inoue K, Masuko-Hongo K, Okamoto M, Nishioka K, Induction of vascular endothelial growth factor and matrix metalloproteinase-3 (stromelysin) by interleukin-1 in human articular chondrocytes and synoviocytes. Rheumatol Int. 2005;26:93-98.
13. Ben-Av P, Crofford LJ, Wilder RL, Hla T, Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372:83-87.
14. Voronov E, Shouval DS, Kreli Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100:2645-2650.
15. Luna JD, Chan CC, Derevjanik NL, et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta- mediated breakdown. J Neurosci Res. 1997:49:268-280.
16. Derevjanik NL, Vinores SA, Xiao WH, et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci. 2002;43:2462-2467.
17. Amin AR, Ichigotani Y, Oo ML, et al. The PLC-PKC cascade is required for IL-1beta-dependent Erk and Akt activation: their role in proliferation. Int J Oncol. 2003;23:1727-1731.
18. Bar D, Apte RN, Voronov E, Dinarello CA, Cohen SA, Continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 2004;18:161-163.
19. Moore JE, McMullen TC, Campbell IL, et al. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest Ophthalmol Vis Sci. 2002;43:2905-2915.
20. Konishi N, Miki C, Yoshida T, Tanaka K, Toiyama Y, Kusunoki M, Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology. 2005;68:138-145.
21. Biswas PS, Banerjee K, Kim B, Rouse BT, Mice transgenic for IL-1 receptor antagonist protein are resistant to herpetic stromal keratitis: possible role for IL-1 in herpetic stromal keratitis pathogenesis. J Immunol. 2004;172:3736-3744
22. Biswas PS, Banerjee K, Zheng M, Rouse BT, Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. J Leukoc Biol. 2004;76:868-875.
23. Danis RP, Bingaman DP, Yang Y, Ladd B, Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 1996;103:2099-2104.
24. Miller H, Miller B, Ishibashi T, Ryan SJ, Pathogenesis of laser-induced choroidal subretinal neovascularization. Invest Ophthalmol Vis Sci. 1990;31:899-908.
25. Ryan SJ. Subretinal neovascularization: natural history of an experimental model. Arch Ophthalmol. 1982;100:1804-1809.
26. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ, Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1985:103:708-711.
27. Edelman JL, Castro MR. Quantitative image analysis of laserinduced choroidal neovascularization in rat. Exp Eye Res. 2000;71:523-533.
28. Gao H, Qiao X, Gao R, Mieler WF, McPherson AR, Holz ER, Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina. Vision Res. 2004;44:349-356.
29. McMenamin, PG. Optimal methods for preparation and immunostaining of iris, ciliary body, and choroidal whole mounts. Invest Ophthalmol Vis Sci. 2000:41:3043-3048.
30. Semkova I, Peters S, Welsandt G, Janicki H, Jordan J, Schraermeyer U, Investigation of laser-induced choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci. 2003;44:5349-5354.
31. Brunn G, Saadi S, Platt J. Constitutive repression of interleukin1alpha in endothelial cells. Circ Res. 2008:102:823-830.
32. Zou Y, Xu X, Chiou GCY, Effect of interleukin-1 blockers, CK112, and CK116 on rat experimental choroidal neovascularization in vivo and endothelial cells in vitro. J Ocul Pharmacol Th. 2006;22:19-25.
33. Olson JL, Courtney RJ, Mandava N, Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol. 2007;125:1221-1224.
34. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
35. Lima e Silva R, Saishin Y, Saishin Y, et al. Suppression and regression of choroidal neovascularization by polyamine analogues. Invest Ophthalmol Vis Sci. 2005;46:3323-3330.
36. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum. 2005;52:1960-1967.
37. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9:47-52.
38. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2006;13:225-234.